UPDATE: Cantor Fitzgerald Initiates Fate Therapeutics With Overweight, $32 Tgt As Firm Thinks Co. 'is pioneering a highly scalable next-generation cell-therapy manufacturing process using induced pluripotent stem cells (iPSCs) that could be first class'
Benzinga_Newsdesk